Isa Dietrich1,2, Gustavo Arruda Braga3, Fernanda Gomes de Melo3, Ana Carolina Calmon da Costa Silva Silva3. 1. Liver, Pancreas and Islets Transplantation, Surgery Division, Department of Gastroenterology, University of São Paulo School of Medicine. LIM 37, Av. Dr. Arnaldo 455 - 3rd floor suíte 3208, Cerqueira Cesar, São Paulo, 01246-903, Brazil. Isa.dietrich@isa.med.br. 2. Division Obesity and Diabetes Center, Organization Oswaldo Cruz German Hospital, R. Cincinato Braga, 37 - 5th floor, Bela Vista, São Paulo, 01246-903, Brazil. Isa.dietrich@isa.med.br. 3. Division Obesity and Diabetes Center, Organization Oswaldo Cruz German Hospital, R. Cincinato Braga, 37 - 5th floor, Bela Vista, São Paulo, 01246-903, Brazil.
Abstract
PURPOSE OF REVIEW: This article reviewed very recent papers (2016) discussing or bringing clinical evidences of the possible common pathways leading to diabetic foot syndrome (DFS) and increased mortality rates. RECENT FINDINGS: Diabetic patients with diabetic foot syndrome have a mortality rate greater than twofold when compared with non-ulcerated diabetics. In addition, the 5-year mortality rate following amputation is estimated at 39-68%, a life expectancy comparable to aggressive types of cancer or advanced congestive heart failure. The majority of patients with diabetic foot ulcer also present insulin resistance, central obesity, dyslipidemia, and hypertension that characterize the metabolic syndrome that, in turn, is associated with an elevated risk of major cardiovascular events. Sensory neuropathy is the primary cause of more the 60% of diabetic foot ulcer. Diabetic peripheral neuropathy is a microvascular complication of diabetes mellitus and in type 2 diabetes, not only hyperglycemia but also other metabolic alterations and persistent inflammatory status due to adiposity play a major role in axon injury. Elevated triglycerides have been showed to be an independent risk factor for lower extremity amputation in diabetic patients. Also, toxic adiposity, oxidative stress, mitochondrial dysfunction, activation of the polyol pathway, accumulation of advanced glycation end products (AGEs), and elevation of inflammatory markers are also implicated in diabetic vascular disease and neuropathy. The hypotheses that the association between DFS and increased rates of mortality reflects the progression of micro- and macrovascular complications are reinforced by the additional association of DFU to renal failure and retinopathy.
PURPOSE OF REVIEW: This article reviewed very recent papers (2016) discussing or bringing clinical evidences of the possible common pathways leading to diabetic foot syndrome (DFS) and increased mortality rates. RECENT FINDINGS:Diabeticpatients with diabetic foot syndrome have a mortality rate greater than twofold when compared with non-ulcerated diabetics. In addition, the 5-year mortality rate following amputation is estimated at 39-68%, a life expectancy comparable to aggressive types of cancer or advanced congestive heart failure. The majority of patients with diabetic foot ulcer also present insulin resistance, central obesity, dyslipidemia, and hypertension that characterize the metabolic syndrome that, in turn, is associated with an elevated risk of major cardiovascular events. Sensory neuropathy is the primary cause of more the 60% of diabetic foot ulcer. Diabetic peripheral neuropathy is a microvascular complication of diabetes mellitus and in type 2 diabetes, not only hyperglycemia but also other metabolic alterations and persistent inflammatory status due to adiposity play a major role in axon injury. Elevated triglycerides have been showed to be an independent risk factor for lower extremity amputation in diabeticpatients. Also, toxic adiposity, oxidative stress, mitochondrial dysfunction, activation of the polyol pathway, accumulation of advanced glycation end products (AGEs), and elevation of inflammatory markers are also implicated in diabetic vascular disease and neuropathy. The hypotheses that the association between DFS and increased rates of mortality reflects the progression of micro- and macrovascular complications are reinforced by the additional association of DFU to renal failure and retinopathy.
Authors: Alessandra M Mantovani; Cristina E P T Fregonesi; Mariana R Palma; Fernanda E Ribeiro; Rômulo A Fernandes; Diego G D Christofaro Journal: Diabetes Metab Syndr Date: 2016-08-23
Authors: Kamel Mohammedi; Mark Woodward; Yoichiro Hirakawa; Sophia Zoungas; Stephen Colagiuri; Pavel Hamet; Stephen Harrap; Neil Poulter; David R Matthews; Michel Marre; John Chalmers Journal: Cardiovasc Diabetol Date: 2016-09-02 Impact factor: 9.951
Authors: Manuel Ángel Gómez-Marcos; José Ignacio Recio-Rodríguez; María Carmen Patino-Alonso; Cristina Agudo-Conde; Emiliano Rodríguez-Sanchez; Jose Angel Maderuelo-Fernandez; Leticia Gómez-Sánchez; Marta Gomez-Sanchez; Luís García-Ortiz Journal: BMJ Open Date: 2016-06-01 Impact factor: 2.692
Authors: Emmanuel Navarro-Flores; Carlos Romero-Morales; Jorge Hugo Villafañe; Ricardo Becerro-de-Bengoa-Vallejo; Daniel López-López; Marta Elena Losa-Iglesias; César Calvo-Lobo; Patricia Palomo-López Journal: Int Wound J Date: 2021-05-03 Impact factor: 3.315
Authors: Ché Matthew Harris; Aiham Albaeni; Roland J Thorpe; Keith C Norris; Marwan S Abougergi Journal: PLoS One Date: 2019-05-29 Impact factor: 3.240
Authors: Jorge A Berlanga-Acosta; Gerardo E Guillén-Nieto; Nadia Rodríguez-Rodríguez; Yssel Mendoza-Mari; Maria Luisa Bringas-Vega; Jorge O Berlanga-Saez; Diana García Del Barco Herrera; Indira Martinez-Jimenez; Sandra Hernandez-Gutierrez; Pedro A Valdés-Sosa Journal: Front Endocrinol (Lausanne) Date: 2020-09-16 Impact factor: 5.555